Galapagos regularly takes part in investor conferences.
February 14, 2022
SVB Leerink Virtual 11th Annual Global Healthcare Conference Virtual
February 24, 2022
Full year 2021 results
February 25, 2022
Webcast Full year 2021 results, 14.00 CET
March 01, 2022
Credit Suisse Healthcare Conference Virtual
March 06, 2022
Raymond James 43rd Annual Institutional Investors Conference Orlando
April 20, 2022
14th Kempen Life Sciences Conference Amsterdam
Galapagos NV (GLPG:NA) / (GLPG) PT Raised to EUR 60.00 at Barclays Capital (from EUR 48.00).
Barclays analyst Emily Field raised the price target on Galapagos.
Valuation Methodology: Our PT of € 60/sh in-line with our NPV; we feel this is appropriate given continued uncertainty around how the incoming CEO may deploy the company's cash balance into replenishing the pipeline. Our prior price target factored in a signficant discount to NPV given the uncertainty around the CEO role, which has now been filled.
Risks which May Impede the Achievement of the Barclays Research Price Target:
Upside case: MANTA safety study reads out positively, and Gilead decides to submit filgotinib for approval in IBD in the US and subsequently gets approval.
Any safety signals for filgotinib in MANTA or failure of the asset in the IBD ph. 3 trials. Value-destructive deals.